• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基于肿瘤炎症微环境活性的外周循环血细胞偏差在切除的进展期肺腺癌中的研究

Peripheral Circulating Blood Cells Deviation Based on Tumor Inflammatory Microenvironment Activity in Resected Upstaged Lung Adenocarcinomas.

作者信息

Bonis Alessandro, Lunardi Francesca, Pagliarini Giulia, Verzeletti Vincenzo, Lione Luigi, Busetto Alberto, Cannone Giorgio, Comacchio Giovanni Maria, Mammana Marco, Faccioli Eleonora, Rebusso Alessandro, Schiavon Marco, Nicotra Samuele, Dell'Amore Andrea, Rea Federico

机构信息

Thoracic Surgery Unit, Department of Cardiac, Thoracic, Vascular Sciences and Public Health-DSCTV, University of Padova, 35128 Padova, Italy.

Pathology Unit, Department of Cardiac, Thoracic, Vascular Sciences and Public Health-DSCTV, University of Padova, 35128 Padova, Italy.

出版信息

J Clin Med. 2024 Dec 13;13(24):7597. doi: 10.3390/jcm13247597.

DOI:10.3390/jcm13247597
PMID:39768520
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11676159/
Abstract

: The tumour inflammatory microenvironment (TIME) reflects a selective activation of the central immune system (IS), particularly T-cells expansion, which leads to immune cells migrating to the target, such as lung cancer, via the bloodstream and lymphatic vessels. In this study, the aim is to investigate whether the distribution of peripheral blood cells varies based on the immune status of patients with lung adenocarcinoma. : This is a single-center retrospective study conducted in the Thoracic Surgery Unit of the University of Padua (Italy) between 1 January 2016 and 1 April 2024. It included patients (>18 years old) with lung adenocarcinoma deemed resectable (cT2bN0M0 or lower) who experienced pathological upstaging (IIB or higher). Patients were classified as TIME-active (with tumour-infiltrating lymphocytes-TILs and/or PD-L1 expression) or TIME-silent (without TILs or PD-L1). According to the TIME status, peripheral blood cell counts with clinical and pathological data were compared between groups using the Fisher's, Pearson's or Wilcoxon's test when appropriate. A Kaplan-Meier estimator investigated overall survival (OS) and recurrence-free survival (RFS) adopting the log-rank test. : Preoperatively, the TIME-a group demonstrated a significantly higher lymphocyte count ( = 0.02) and a lower absolute neutrophil rate ( = 0.01) than TIME-s. These differences persisted after resection ( = 0.06 and = 0.02) while they became similar one month after surgery ( = 1 and = 0.32). The neutrophil-to-lymphocyte ratio-NLR showed similar trends ( = 0.01 and = 1). Better OS and RFS were shown in the TIME-a group ( = 0.02 and 0.03, respectively). : Resected upstaged lung adenocarcinomas show distinct peripheral blood cell profiles based on immune status. TIME-active patients had a significantly lower NLR, which normalized post-surgery. Surgical resection may help restore native immune surveillance.

摘要

肿瘤炎性微环境(TIME)反映了中枢免疫系统(IS)的选择性激活,尤其是T细胞的扩增,这会导致免疫细胞通过血液和淋巴管迁移至靶标,如肺癌。在本研究中,目的是调查外周血细胞的分布是否会因肺腺癌患者的免疫状态而有所不同。

这是一项在意大利帕多瓦大学胸外科进行的单中心回顾性研究,时间跨度为2016年1月1日至2024年4月1日。研究纳入了年龄大于18岁、被认为可切除(cT2bN0M0或更低)但病理分期上调(IIB或更高)的肺腺癌患者。患者被分为TIME激活型(有肿瘤浸润淋巴细胞-TILs和/或PD-L1表达)或TIME沉默型(无TILs或PD-L1)。根据TIME状态,在适当情况下,使用Fisher检验、Pearson检验或Wilcoxon检验对组间的外周血细胞计数与临床和病理数据进行比较。采用Kaplan-Meier估计器,并通过对数秩检验研究总生存期(OS)和无复发生存期(RFS)。

术前,TIME激活组的淋巴细胞计数显著高于TIME沉默组(P = 0.02),绝对中性粒细胞率低于TIME沉默组(P = 0.01)。这些差异在切除后仍然存在(P = 0.06和P = 0.02),而在术后1个月时变得相似(P = 1和P = 0.32)。中性粒细胞与淋巴细胞比值-NLR显示出相似的趋势(P = 0.01和P = 1)。TIME激活组的OS和RFS表现更好(分别为P = 0.02和0.03)。

切除的分期上调肺腺癌根据免疫状态显示出不同的外周血细胞特征。TIME激活型患者的NLR显著更低,术后恢复正常。手术切除可能有助于恢复天然免疫监视。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bd2f/11676159/01a105a2e0a4/jcm-13-07597-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bd2f/11676159/0a436171c98d/jcm-13-07597-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bd2f/11676159/b12559889c31/jcm-13-07597-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bd2f/11676159/c48dcdee08ec/jcm-13-07597-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bd2f/11676159/01a105a2e0a4/jcm-13-07597-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bd2f/11676159/0a436171c98d/jcm-13-07597-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bd2f/11676159/b12559889c31/jcm-13-07597-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bd2f/11676159/c48dcdee08ec/jcm-13-07597-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bd2f/11676159/01a105a2e0a4/jcm-13-07597-g004.jpg

相似文献

1
Peripheral Circulating Blood Cells Deviation Based on Tumor Inflammatory Microenvironment Activity in Resected Upstaged Lung Adenocarcinomas.基于肿瘤炎症微环境活性的外周循环血细胞偏差在切除的进展期肺腺癌中的研究
J Clin Med. 2024 Dec 13;13(24):7597. doi: 10.3390/jcm13247597.
2
Tumor inflammatory microenvironment contribution to survival in resected upstaged adenocarcinomas.肿瘤炎性微环境对切除的进展期腺癌患者生存的影响
Eur J Surg Oncol. 2024 Jul;50(7):108444. doi: 10.1016/j.ejso.2024.108444. Epub 2024 May 28.
3
Prognostic impact of neutrophils-to-lymphocytes ratio (NLR), PD-L1 expression, and tumor immune microenvironment in laryngeal cancer.中性粒细胞与淋巴细胞比值(NLR)、程序性死亡受体配体1(PD-L1)表达及肿瘤免疫微环境对喉癌的预后影响
Ann Diagn Pathol. 2021 Feb;50:151657. doi: 10.1016/j.anndiagpath.2020.151657. Epub 2020 Nov 5.
4
Characterization of CD66b and its relationship between immune checkpoints and their synergistic impact in the prognosis of surgically resected lung adenocarcinoma.CD66b 的特征及其与免疫检查点之间的关系及其对手术切除肺腺癌预后的协同影响。
Lung Cancer. 2021 Oct;160:84-91. doi: 10.1016/j.lungcan.2021.08.012. Epub 2021 Aug 28.
5
Is It Unnecessary to Assess Tumor Stroma-Infiltrating Lymphocytes in Localized Lung Adenocarcinomas?在局限性肺腺癌中评估肿瘤基质浸润淋巴细胞是否必要?
Tanaffos. 2024 Feb;23(2):129-138.
6
Clinical significance of programmed cell death-ligand expression in small bowel adenocarcinoma is determined by the tumor microenvironment.程序性细胞死亡配体表达在小肠腺癌中的临床意义取决于肿瘤微环境。
World J Gastroenterol. 2023 Oct 28;29(40):5566-5581. doi: 10.3748/wjg.v29.i40.5566.
7
LAG-3 Protein Expression in Non-Small Cell Lung Cancer and Its Relationship with PD-1/PD-L1 and Tumor-Infiltrating Lymphocytes.LAG-3 蛋白在非小细胞肺癌中的表达及其与 PD-1/PD-L1 和肿瘤浸润淋巴细胞的关系。
J Thorac Oncol. 2017 May;12(5):814-823. doi: 10.1016/j.jtho.2017.01.019. Epub 2017 Jan 26.
8
[CD45RO⁺ Memory T Lymphocytes As A Candidate Marker for Non-small Cell Lung Cancer].[CD45RO⁺记忆性T淋巴细胞作为非小细胞肺癌的候选标志物]
Zhongguo Fei Ai Za Zhi. 2021 Apr 20;24(4):254-264. doi: 10.3779/j.issn.1009-3419.2021.103.05.
9
The landscape of immune microenvironment in lung adenocarcinoma and squamous cell carcinoma based on PD-L1 expression and tumor-infiltrating lymphocytes.基于 PD-L1 表达和肿瘤浸润淋巴细胞的肺腺癌和鳞状细胞癌免疫微环境景观。
Cancer Med. 2019 Dec;8(17):7207-7218. doi: 10.1002/cam4.2580. Epub 2019 Oct 11.
10
Combination of PD-L1 expression and NLR as prognostic marker in patients with surgically resected non-small cell lung cancer.PD-L1表达与中性粒细胞与淋巴细胞比值联合作为手术切除的非小细胞肺癌患者的预后标志物
J Cancer. 2019 Oct 22;10(26):6703-6710. doi: 10.7150/jca.34469. eCollection 2019.

本文引用的文献

1
Characteristics of tumor microenvironment and novel immunotherapeutic strategies for non-small cell lung cancer.非小细胞肺癌的肿瘤微环境特征及新型免疫治疗策略
J Natl Cancer Cent. 2022 Oct 20;2(4):243-262. doi: 10.1016/j.jncc.2022.10.002. eCollection 2022 Dec.
2
Tumor inflammatory microenvironment contribution to survival in resected upstaged adenocarcinomas.肿瘤炎性微环境对切除的进展期腺癌患者生存的影响
Eur J Surg Oncol. 2024 Jul;50(7):108444. doi: 10.1016/j.ejso.2024.108444. Epub 2024 May 28.
3
Comprehensive peripheral blood immunoprofiling reveals five immunotypes with immunotherapy response characteristics in patients with cancer.
全面外周血免疫分析揭示了癌症患者中具有免疫治疗反应特征的五种免疫表型。
Cancer Cell. 2024 May 13;42(5):759-779.e12. doi: 10.1016/j.ccell.2024.04.008.
4
The prognostic value and model construction of inflammatory markers for patients with non-small cell lung cancer.炎症标志物对非小细胞肺癌患者的预后价值及模型构建。
Sci Rep. 2024 Mar 30;14(1):7568. doi: 10.1038/s41598-024-57814-4.
5
Tumor-infiltrating lymphocytes predict efficacy of immunotherapy in advanced non-small cell lung cancer: a single-center retrospective cohort study.肿瘤浸润淋巴细胞预测晚期非小细胞肺癌免疫治疗的疗效:一项单中心回顾性队列研究。
Acta Oncol. 2023 Aug;62(8):853-860. doi: 10.1080/0284186X.2023.2228991. Epub 2023 Jun 28.
6
Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer.帕博利珠单抗用于早期非小细胞肺癌的围手术期治疗。
N Engl J Med. 2023 Aug 10;389(6):491-503. doi: 10.1056/NEJMoa2302983. Epub 2023 Jun 3.
7
Neutrophil diversity in inflammation and cancer.中性粒细胞在炎症和癌症中的多样性。
Front Immunol. 2023 Apr 26;14:1180810. doi: 10.3389/fimmu.2023.1180810. eCollection 2023.
8
Prognostic significance of tumor infiltrating lymphocytes on first-line pembrolizumab efficacy in advanced non-small cell lung cancer.肿瘤浸润淋巴细胞对晚期非小细胞肺癌一线帕博利珠单抗疗效的预后意义
Discov Oncol. 2023 Jan 20;14(1):6. doi: 10.1007/s12672-023-00615-4.
9
Tumour-infiltrating lymphocytes: from prognosis to treatment selection.肿瘤浸润淋巴细胞:从预后到治疗选择。
Br J Cancer. 2023 Feb;128(3):451-458. doi: 10.1038/s41416-022-02119-4. Epub 2022 Dec 23.
10
Peripheral blood markers predict immunotherapeutic efficacy in patients with advanced non-small cell lung cancer: A multicenter study.外周血标志物预测晚期非小细胞肺癌患者的免疫治疗疗效:一项多中心研究。
Front Genet. 2022 Oct 20;13:1016085. doi: 10.3389/fgene.2022.1016085. eCollection 2022.